Limits...
Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.

Uchida J, Imamura F, Kukita Y, Oba S, Kumagai T, Nishino K, Inoue T, Kimura M, Kato K - Cancer Sci. (2016)

Bottom Line: Decreased ctDNA level in response to the initiation of EGFR-TKI was observed in 4 of 6 eligible patients.In another patient, the T790M ctDNA represented cell subpopulations that respond to cytotoxic agents differently from the major population.Considering the high incidence, ctDNA could be a clinical parameter to complement information from image analyses.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.

Show MeSH

Related in: MedlinePlus

Distribution of plasma mutation (PM) scores of the “mutation‐positive in plasma” samples from lung cancer patients. Vertical axis, fraction of samples (%) within the PM score range; horizontal axis, PM score range; black bar, non‐disease progression samples; white bar, disease progression samples. (a) Exon 19 deletion/L858R. (b) T790M.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814247&req=5

cas12860-fig-0001: Distribution of plasma mutation (PM) scores of the “mutation‐positive in plasma” samples from lung cancer patients. Vertical axis, fraction of samples (%) within the PM score range; horizontal axis, PM score range; black bar, non‐disease progression samples; white bar, disease progression samples. (a) Exon 19 deletion/L858R. (b) T790M.

Mentions: We compared the distributions of the PM scores with the non‐PD and PD “mutation‐positive in plasma” samples (Fig. 1). The PD samples tended to be distributed in fractions of high PM scores compared with non‐PD samples.


Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.

Uchida J, Imamura F, Kukita Y, Oba S, Kumagai T, Nishino K, Inoue T, Kimura M, Kato K - Cancer Sci. (2016)

Distribution of plasma mutation (PM) scores of the “mutation‐positive in plasma” samples from lung cancer patients. Vertical axis, fraction of samples (%) within the PM score range; horizontal axis, PM score range; black bar, non‐disease progression samples; white bar, disease progression samples. (a) Exon 19 deletion/L858R. (b) T790M.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814247&req=5

cas12860-fig-0001: Distribution of plasma mutation (PM) scores of the “mutation‐positive in plasma” samples from lung cancer patients. Vertical axis, fraction of samples (%) within the PM score range; horizontal axis, PM score range; black bar, non‐disease progression samples; white bar, disease progression samples. (a) Exon 19 deletion/L858R. (b) T790M.
Mentions: We compared the distributions of the PM scores with the non‐PD and PD “mutation‐positive in plasma” samples (Fig. 1). The PD samples tended to be distributed in fractions of high PM scores compared with non‐PD samples.

Bottom Line: Decreased ctDNA level in response to the initiation of EGFR-TKI was observed in 4 of 6 eligible patients.In another patient, the T790M ctDNA represented cell subpopulations that respond to cytotoxic agents differently from the major population.Considering the high incidence, ctDNA could be a clinical parameter to complement information from image analyses.

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.

Show MeSH
Related in: MedlinePlus